Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy?
| Title: | Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy? |
|---|---|
| Authors: | Howard L Kaufman, Hongbin Wang, Dipongkor Saha, Samuel D Rabkin, Mia Borlongan, Uyen Le, Hans J Nauwynck |
| Source: | Journal for ImmunoTherapy of Cancer, Vol 12, Iss 5 (2024) |
| Publisher Information: | BMJ Publishing Group, 2024. |
| Publication Year: | 2024 |
| Collection: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: | Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: | Cytokines are small proteins that regulate the growth and functional activity of immune cells, and several have been approved for cancer therapy. Oncolytic viruses are agents that mediate antitumor activity by directly killing tumor cells and inducing immune responses. Talimogene laherparepvec is an oncolytic herpes simplex virus type 1 (oHSV), approved for the treatment of recurrent melanoma, and the virus encodes the human cytokine, granulocyte-macrophage colony-stimulating factor (GM-CSF). A significant advantage of oncolytic viruses is the ability to deliver therapeutic payloads to the tumor site that can help drive antitumor immunity. While cytokines are especially interesting as payloads, the optimal cytokine(s) used in oncolytic viruses remains controversial. In this review, we highlight preliminary data with several cytokines and chemokines, including GM-CSF, interleukin 12, FMS-like tyrosine kinase 3 ligand, tumor necrosis factor α, interleukin 2, interleukin 15, interleukin 18, chemokine (C-C motif) ligand 2, chemokine (C-C motif) ligand 5, chemokine (C-X-C motif) ligand 4, or their combinations, and show how these payloads can further enhance the antitumor immunity of oHSV. A better understanding of cytokine delivery by oHSV can help improve clinical benefit from oncolytic virus immunotherapy in patients with cancer. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 2051-1426 |
| Relation: | https://jitc.bmj.com/content/12/5/e008025.full; https://doaj.org/toc/2051-1426 |
| DOI: | 10.1136/jitc-2023-008025 |
| Access URL: | https://doaj.org/article/ae1324671e874fbf8b0558f501e18cfa |
| Accession Number: | edsdoj.1324671e874fbf8b0558f501e18cfa |
| Database: | Directory of Open Access Journals |
| FullText | Text: Availability: 0 CustomLinks: – Url: https://resolver.ebsco.com/c/xy5jbn/result?sid=EBSCO:edsdoj&genre=article&issn=20511426&ISBN=&volume=12&issue=5&date=20240501&spage=&pages=&title=Journal for ImmunoTherapy of Cancer&atitle=Cytokine-armed%20oncolytic%20herpes%20simplex%20viruses%3A%20a%20game-changer%20in%20cancer%20immunotherapy%3F&aulast=Howard%20L%20Kaufman&id=DOI:10.1136/jitc-2023-008025 Name: Full Text Finder (for New FTF UI) (s8985755) Category: fullText Text: Find It @ SCU Libraries MouseOverText: Find It @ SCU Libraries – Url: https://doaj.org/article/ae1324671e874fbf8b0558f501e18cfa Name: EDS - DOAJ (s8985755) Category: fullText Text: View record from DOAJ MouseOverText: View record from DOAJ |
|---|---|
| Header | DbId: edsdoj DbLabel: Directory of Open Access Journals An: edsdoj.1324671e874fbf8b0558f501e18cfa RelevancyScore: 1008 AccessLevel: 3 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 1008.02886962891 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy? – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Howard+L+Kaufman%22">Howard L Kaufman</searchLink><br /><searchLink fieldCode="AR" term="%22Hongbin+Wang%22">Hongbin Wang</searchLink><br /><searchLink fieldCode="AR" term="%22Dipongkor+Saha%22">Dipongkor Saha</searchLink><br /><searchLink fieldCode="AR" term="%22Samuel+D+Rabkin%22">Samuel D Rabkin</searchLink><br /><searchLink fieldCode="AR" term="%22Mia+Borlongan%22">Mia Borlongan</searchLink><br /><searchLink fieldCode="AR" term="%22Uyen+Le%22">Uyen Le</searchLink><br /><searchLink fieldCode="AR" term="%22Hans+J+Nauwynck%22">Hans J Nauwynck</searchLink> – Name: TitleSource Label: Source Group: Src Data: Journal for ImmunoTherapy of Cancer, Vol 12, Iss 5 (2024) – Name: Publisher Label: Publisher Information Group: PubInfo Data: BMJ Publishing Group, 2024. – Name: DatePubCY Label: Publication Year Group: Date Data: 2024 – Name: Subset Label: Collection Group: HoldingsInfo Data: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens – Name: Subject Label: Subject Terms Group: Su Data: <searchLink fieldCode="DE" term="%22Neoplasms%2E+Tumors%2E+Oncology%2E+Including+cancer+and+carcinogens%22">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</searchLink><br /><searchLink fieldCode="DE" term="%22RC254-282%22">RC254-282</searchLink> – Name: Abstract Label: Description Group: Ab Data: Cytokines are small proteins that regulate the growth and functional activity of immune cells, and several have been approved for cancer therapy. Oncolytic viruses are agents that mediate antitumor activity by directly killing tumor cells and inducing immune responses. Talimogene laherparepvec is an oncolytic herpes simplex virus type 1 (oHSV), approved for the treatment of recurrent melanoma, and the virus encodes the human cytokine, granulocyte-macrophage colony-stimulating factor (GM-CSF). A significant advantage of oncolytic viruses is the ability to deliver therapeutic payloads to the tumor site that can help drive antitumor immunity. While cytokines are especially interesting as payloads, the optimal cytokine(s) used in oncolytic viruses remains controversial. In this review, we highlight preliminary data with several cytokines and chemokines, including GM-CSF, interleukin 12, FMS-like tyrosine kinase 3 ligand, tumor necrosis factor α, interleukin 2, interleukin 15, interleukin 18, chemokine (C-C motif) ligand 2, chemokine (C-C motif) ligand 5, chemokine (C-X-C motif) ligand 4, or their combinations, and show how these payloads can further enhance the antitumor immunity of oHSV. A better understanding of cytokine delivery by oHSV can help improve clinical benefit from oncolytic virus immunotherapy in patients with cancer. – Name: TypeDocument Label: Document Type Group: TypDoc Data: article – Name: Format Label: File Description Group: SrcInfo Data: electronic resource – Name: Language Label: Language Group: Lang Data: English – Name: ISSN Label: ISSN Group: ISSN Data: 2051-1426 – Name: NoteTitleSource Label: Relation Group: SrcInfo Data: https://jitc.bmj.com/content/12/5/e008025.full; https://doaj.org/toc/2051-1426 – Name: DOI Label: DOI Group: ID Data: 10.1136/jitc-2023-008025 – Name: URL Label: Access URL Group: URL Data: <link linkTarget="URL" linkTerm="https://doaj.org/article/ae1324671e874fbf8b0558f501e18cfa" linkWindow="_blank">https://doaj.org/article/ae1324671e874fbf8b0558f501e18cfa</link> – Name: AN Label: Accession Number Group: ID Data: edsdoj.1324671e874fbf8b0558f501e18cfa |
| PLink | https://login.libproxy.scu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.1324671e874fbf8b0558f501e18cfa |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1136/jitc-2023-008025 Languages: – Text: English Subjects: – SubjectFull: Neoplasms. Tumors. Oncology. Including cancer and carcinogens Type: general – SubjectFull: RC254-282 Type: general Titles: – TitleFull: Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy? Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Howard L Kaufman – PersonEntity: Name: NameFull: Hongbin Wang – PersonEntity: Name: NameFull: Dipongkor Saha – PersonEntity: Name: NameFull: Samuel D Rabkin – PersonEntity: Name: NameFull: Mia Borlongan – PersonEntity: Name: NameFull: Uyen Le – PersonEntity: Name: NameFull: Hans J Nauwynck IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 05 Type: published Y: 2024 Identifiers: – Type: issn-print Value: 20511426 Numbering: – Type: volume Value: 12 – Type: issue Value: 5 Titles: – TitleFull: Journal for ImmunoTherapy of Cancer Type: main |
| ResultId | 1 |